Streetbeat News

Analyst Ratings

FSLY

Fastly (NYSE:FSLY) has received mixed analyst ratings in the last quarter, with 1 bullish, 3 indifferent, and 2 somewhat bearish ratings. The average 12-month price target for the stock is $15.75, which has increased by 26.0% over the past month.

Portfolio Pulse from Benzinga Insights

June 23, 2023 | 4:01 pm

NEX

In the last quarter, NexTier Oilfield (NYSE:NEX) received 2 bullish, 2 somewhat bullish, 3 indifferent, and 1 somewhat bearish analyst ratings. The company has an average 12-month price target of $10.71, a 16.0% decrease from the previous average of $12.75.

Portfolio Pulse from Benzinga Insights

June 23, 2023 | 4:01 pm

FLYW

Over the past 3 months, 12 analysts have published their opinion on Flywire (NASDAQ:FLYW) stock, with an average 12-month price target of $35.58, up 8.91% from the previous average of $32.67. The majority of the ratings are bullish or somewhat bullish.

Portfolio Pulse from Benzinga Insights

June 23, 2023 | 4:01 pm

AAPL

Over the past 3 months, 48 analysts have published their opinions on Apple (NASDAQ:AAPL) stock, with an average price target of $186.62, slightly above the current price of $186.5. The current average has increased by 5.82% from the previous average price target of $176.35.

Portfolio Pulse from Benzinga Insights

June 23, 2023 | 4:00 pm

GPN

Analysts have provided various ratings for Global Payments (NYSE:GPN) within the last quarter, with an average 12-month price target of $135.81. The current average has decreased by 1.27% from the previous average price target of $137.56.

Portfolio Pulse from Benzinga Insights

June 23, 2023 | 4:00 pm

ITCI

Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a $90 price target.

Portfolio Pulse from richadhand@benzinga.com

June 23, 2023 | 4:00 pm

HRMY

Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a $75 price target.

Portfolio Pulse from richadhand@benzinga.com

June 23, 2023 | 3:59 pm

VRTX

Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and maintained a $365 price target.

Portfolio Pulse from richadhand@benzinga.com

June 23, 2023 | 3:58 pm

REGN

Cantor Fitzgerald analyst Alethia Young reiterated a Neutral rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and maintained an $815 price target.

Portfolio Pulse from richadhand@benzinga.com

June 23, 2023 | 3:57 pm

ALNY

Cantor Fitzgerald analyst Olivia Brayer reiterated a Neutral rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a $200 price target.

Portfolio Pulse from richadhand@benzinga.com

June 23, 2023 | 3:56 pm